FindTrial
Sign In

Role of blood protein markers in Parkinsonian Syndrome

TO STUDY THE ROLE OF BLOOD BIOMARKERS DJ-1 AND APOA-1 IN IDOPATHIC PARKINSON DISEASE AND PARKINSON PLUS SYNDROMES

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/11/010423
Enrollment
200
Registered
2017-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Parkinsons disease and Parkinson Plus Syndrome patients

Interventions

None listed

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients with clinical diagnosis of Idiopathic Parkinsonâ??s Disease based on UK Parkinsonâ??s Disease Society Brain Bank clinical diagnostic criteria 2.All patients with clinical diagnosis of Parkinson Plus Syndrome

Exclusion criteria

Exclusion criteria: Secondary parkinsonism a)History of repeated strokes with stepwise progression of parkinsonian features b)History of repeated head injury c)History of definite encephalitis d)Neuroleptic treatment at onset of symptoms e)Presence of cerebral tumor or communicating hydrocephalus on imaging study f)MPTP exposure g)Sustained remission

Design outcomes

Primary

MeasureTime frame
1.To study the role of serum biomarkers DJ-1 and Apo A-1 in diagnosis of Idiopathic Parkinsonâ??s Disease and Parkinson plus syndromes.Timepoint: 6 months—

Secondary

MeasureTime frame
To study the role of DJ1 & ApoA1 biomarkers in differentiating Idiopathic Parkinson Disease and Parkinson plus syndromes.Timepoint: 6 months—

Countries

India

Contacts

Public ContactDr Manish Modi

PGIMER

modim72@yahoo.com9876197533

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026